SG47905A1 - Stabilised antibodies - Google Patents

Stabilised antibodies

Info

Publication number
SG47905A1
SG47905A1 SG1996005153A SG1996005153A SG47905A1 SG 47905 A1 SG47905 A1 SG 47905A1 SG 1996005153 A SG1996005153 A SG 1996005153A SG 1996005153 A SG1996005153 A SG 1996005153A SG 47905 A1 SG47905 A1 SG 47905A1
Authority
SG
Singapore
Prior art keywords
immunoglobulin
pct
copper ions
sec
date
Prior art date
Application number
SG1996005153A
Other languages
English (en)
Inventor
Marjorie Smith
Valentina Riveros-Rojas
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10703637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG47905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SG47905A1 publication Critical patent/SG47905A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
SG1996005153A 1991-10-28 1992-10-27 Stabilised antibodies SG47905A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919122820A GB9122820D0 (en) 1991-10-28 1991-10-28 Stabilised antibodies

Publications (1)

Publication Number Publication Date
SG47905A1 true SG47905A1 (en) 1998-04-17

Family

ID=10703637

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005153A SG47905A1 (en) 1991-10-28 1992-10-27 Stabilised antibodies

Country Status (17)

Country Link
US (2) US5654403A (ja)
EP (1) EP0612251B1 (ja)
JP (1) JP2881499B2 (ja)
AT (1) ATE161191T1 (ja)
AU (1) AU674290B2 (ja)
CA (1) CA2121257C (ja)
DE (1) DE69223641T2 (ja)
DK (1) DK0612251T3 (ja)
ES (1) ES2112338T3 (ja)
GB (1) GB9122820D0 (ja)
GR (1) GR3025931T3 (ja)
HK (1) HK1004325A1 (ja)
IL (1) IL103560A (ja)
MY (1) MY110207A (ja)
SG (1) SG47905A1 (ja)
WO (1) WO1993008837A1 (ja)
ZA (1) ZA928296B (ja)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
PT907735E (pt) * 1996-05-24 2006-06-30 Biogen Idec Inc Moduladores da regeneracao de tecidos
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
DK1068238T3 (da) * 1998-04-02 2013-01-14 Xintela Ab Integrinheterodimer og subunit deraf
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
WO2000058480A1 (fr) * 1999-03-29 2000-10-05 Kansai Technology Licensing Organization Co., Ltd. Nouvelle cytidine desaminase
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
NZ528483A (en) * 2001-04-05 2008-03-28 Astellas Pharma Inc Anti-osteopontin antibody and use thereof
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
AU2004277466C1 (en) * 2003-10-01 2022-06-23 Kyowa Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
WO2005035573A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
PT1730191E (pt) 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US20090238820A1 (en) * 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
WO2007135546A2 (en) * 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2008045373A2 (en) * 2006-10-06 2008-04-17 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
GB0904355D0 (en) * 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2012114854A (ru) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
US20110071276A1 (en) * 2009-09-24 2011-03-24 Xbiotech, Inc. Method of modifying a monoclonal antibody
CA2778401C (en) * 2009-10-21 2019-08-13 Hiroshima University Integrin alpha 8-beta 1-specific monoclonal antibody
JP5850860B2 (ja) 2010-01-28 2016-02-03 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｃｄ１２７結合タンパク質
WO2011098424A2 (en) 2010-02-09 2011-08-18 Glaxo Group Limited Treatment of a metabolic disorder
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
KR20130098279A (ko) 2010-06-18 2013-09-04 엑스바이오테크, 인크. 관절염 치료
ES2856723T3 (es) 2010-08-23 2021-09-28 Janssen Biotech Inc Tratamiento para enfermedades neoplásicas
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013043973A2 (en) 2011-09-23 2013-03-28 Xbiotech, Inc. Cachexia treatment
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2968550B1 (en) * 2013-03-14 2018-11-14 Ffe Therapeutics LLC Compositions and methods for treating angiogenesis-related disorders
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
PT3334747T (pt) 2015-08-13 2023-12-12 Amgen Inc Formulação de gonadotrofina líquida estável
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
CN110408600A (zh) * 2018-12-10 2019-11-05 浙江工商大学 一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
CA1308023C (en) * 1988-07-29 1992-09-29 William Austin James Mcauley Immunoglobulin extraction utilizing properties of colloidal solutions
US4933435A (en) * 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin

Also Published As

Publication number Publication date
CA2121257C (en) 1999-07-13
ZA928296B (en) 1994-04-28
WO1993008837A1 (en) 1993-05-13
MY110207A (en) 1998-02-28
US5654403A (en) 1997-08-05
ATE161191T1 (de) 1998-01-15
CA2121257A1 (en) 1993-05-13
IL103560A0 (en) 1993-03-15
US5792838A (en) 1998-08-11
GB9122820D0 (en) 1991-12-11
ES2112338T3 (es) 1998-04-01
IL103560A (en) 1998-02-08
DE69223641D1 (de) 1998-01-29
GR3025931T3 (en) 1998-04-30
JP2881499B2 (ja) 1999-04-12
EP0612251A1 (en) 1994-08-31
EP0612251B1 (en) 1997-12-17
JPH07502497A (ja) 1995-03-16
DK0612251T3 (da) 1998-04-27
HK1004325A1 (en) 1998-11-20
AU674290B2 (en) 1996-12-19
AU2872992A (en) 1993-06-07
DE69223641T2 (de) 1998-04-09

Similar Documents

Publication Publication Date Title
GB9122820D0 (en) Stabilised antibodies
DE69433010D1 (de) Verfahren zur darstellung von oligonukleotiden
DE69031909D1 (de) Monoklonale antikörper für metall kationen
IE830823L (en) Process and reagent for the determination of low density¹lipoproteins in body fluids
DE3069460D1 (en) Production of immunoglobulin having a high monomer content
FI933546A0 (fi) Kemisk process
IL117157A (en) Preparation of factor ix form biological sources
DE59309952D1 (de) Verfahren zur quantitativen Aufreinigung von Glycolipiden
ATE128104T1 (de) Verfahren und vorrichtung zur behandlung eines kaliumchloridgemenges.
AR246526A1 (es) Procedimiento para preparar compuesto de macrolida y composicion que los incluye para combatir plagas excluida su aplicacion en animales y el hombre.
JPS5240494A (en) Process for producing needle crystal fiber of gypsum
DE3650570D1 (de) Verfahren und Reagenz zur Bestimmung des Follikel stimulierenden Hormons sowie hierzu geeignete monoklonale Antikörper
ATE135342T1 (de) Verfahren zur herstellung von diacetylrhein
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
ATE148694T1 (de) Verfahren zur herstellung von 3(5)- methylpyrazolen
DE69012488D1 (de) Verfahren zur Herstellung von Diamant-Einkristallen durch chemische Dampfabscheidung.
DE3572649D1 (en) A mixture of diastereoisomer compounds, as obtained from (-)-5-(1-hydroxy-1-methylethyl)-2-methyl-2-cyclohexene-1-one, having mucose-cretolytic activity, a process for its preparation and pharmaceutical compositions containing the same
JPS5777093A (en) Synthesizing method for compound semiconductor
ES8203164A1 (es) Procedimiento para obtener silicio de grado solar